New Zealand markets open in 9 hours 23 minutes

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (002932.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
17.50+0.58 (+3.43%)
At close: 03:04PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 3.93B
Enterprise value 2.85B
Trailing P/E 2.04
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)9.49
Price/book (mrq)0.65
Enterprise value/revenue 6.52
Enterprise value/EBITDA 28.22

Trading information

Stock price history

Beta (5Y monthly) 0.52
52-week change 3-33.25%
S&P500 52-week change 324.96%
52-week high 326.18
52-week low 314.81
50-day moving average 319.41
200-day moving average 321.41

Share statistics

Avg vol (3-month) 33.14M
Avg vol (10-day) 31.63M
Shares outstanding 5232.52M
Implied shares outstanding 6235.27M
Float 8122.35M
% held by insiders 148.54%
% held by institutions 14.23%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.12
Forward annual dividend yield 40.71%
Trailing annual dividend rate 32.48
Trailing annual dividend yield 314.67%
5-year average dividend yield 46.14
Payout ratio 41,121.21%
Dividend date 3N/A
Ex-dividend date 428 May 2024
Last split factor 21.49:1
Last split date 306 Jun 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 13.98%
Operating margin (ttm)-20.94%

Management effectiveness

Return on assets (ttm)4.50%
Return on equity (ttm)9.06%

Income statement

Revenue (ttm)3.69B
Revenue per share (ttm)16.03
Quarterly revenue growth (yoy)-96.00%
Gross profit (ttm)N/A
EBITDA 610.19M
Net income avi to common (ttm)515.33M
Diluted EPS (ttm)-0.02
Quarterly earnings growth (yoy)-97.00%

Balance sheet

Total cash (mrq)2.43B
Total cash per share (mrq)10.46
Total debt (mrq)169.11M
Total debt/equity (mrq)2.65%
Current ratio (mrq)3.61
Book value per share (mrq)26.15

Cash flow statement

Operating cash flow (ttm)2.28B
Levered free cash flow (ttm)2B